InvestorsHub Logo
Followers 1
Posts 24
Boards Moderated 0
Alias Born 10/24/2018

Re: north40000 post# 176087

Thursday, 02/14/2019 8:53:32 PM

Thursday, February 14, 2019 8:53:32 PM

Post# of 426996
Hi North,

I just received my monthly newsletter Worst Pills, Best Pills News published by Public Citizen. The letter from the Editor Dr. Michael Carome is about AcelRx drug Dsuvia. The following is all quoted from the article.

"The drug is five to 10 times more potent than fentanyl and 1,000 times more potent than morphine.

Clinical trials of Dsuvia paradoxically showed that it was not very effective for treating pain following minor surgical procedures. However, the drug does carry significant risks of impaired breathing, diversion, abuse and death.

In a highly unusual move, the chair of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee, Dr. Rayford Brown, on October 22,2018 joined Public Citizen in urging the FDA to reject the application." Sublingual sufentanil represents a danger to the general public health and will make our job of protecting Americans more difficult."

Unfortunately it was approved on November 2, 2018. In 2017 the opioid addiction crisis led to 47,000 deaths in the U.S. Amazing, Vasepa should be a no brainer.

Hope the info is useful.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News